Journal of Clinical Oncology

Vol. 44, Issue 2_suppl Issue 2_suppl 2026
818
Articles

Articles in this Issue

Locoregional therapy for hepatocellular carcinoma before transplant: Impact on tumor necrosis, tumor recurrence, and long-term survival.

Yasaman Rahimi, George Sidrak, Rhaya Murray et al. Jan 10, 2026 pp. 579-579 10.1200/jco.2026.44.2_suppl.579

579 Background: To assess the effectiveness of different pre-transplant loco-regional therapy (LRT) approaches in patients...

Clonal hematopoiesis in GI cancer: Frequent but not a predictor of oxaliplatin neuropathy.

Zhuoer Xie, Solomon Alhassan, Todd C. Knepper et al. Jan 10, 2026 pp. 826-826 10.1200/jco.2026.44.2_suppl.826

826 Background: Oxaliplatin (OXA) is a cornerstone therapy for gastrointestinal (GI) cancers, but chemotherapy-induced per...

Impact of routine collection of electronic patient-reported outcome measures (ePROMs) coupled with a collaborative care (CC)-based symptom intervention in patients with early-onset colorectal cancer (eoCRC).

Michael H. Storandt, Zhaohui Jin, Kathryn Jean Ruddy et al. Jan 10, 2026 pp. 64-64 10.1200/jco.2026.44.2_suppl.64

64 Background: The incidence of eoCRC (diagnosed at age <50) is increasing. We have previously shown higher rates of se...

Conditional survival after surgical resection of well-differentiated pancreatic neuroendocrine tumors: A NDCB analysis.

Aman Singla, Gautam Kumar Malhotra Jan 10, 2026 pp. 631-631 10.1200/jco.2026.44.2_suppl.631

631 Background: Surgical resection remains the standard treatment for low-grade pancreatic neuroendocrine tumors (PanNETs)...

A phase 2 study to investigate the efficacy and safety of acoustic cluster therapy with modified FOLFIRINOX in patients with locally advanced pancreatic cancer.

Erin Pierce, Matthew Siegel, Katie Morgan et al. Jan 10, 2026 10.1200/jco.2026.44.2_suppl.tps795

TPS795 Background: Patients with advanced pancreatic ductal adenocarcinoma (PDAC) face limited treatment options due to th...

Neoadjuvant adebrelimab plus SOX and nab-paclitaxel in resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: A multicentre, single-arm, prospective phase II trial.

Pin Liang, Jie Zhang, Haitao Duan et al. Jan 10, 2026 pp. 344-344 10.1200/jco.2026.44.2_suppl.344

344 Background: We report preliminary results from an ongoing single-arm phase II clinical trial evaluating neoadjuvant ad...

Peptide receptor radionuclide therapy (Lu-177 PRRT) in neuroendocrine tumors (NET) over 16 years: Single institution experience.

Ali H. Aljubran, Ahmed Almuhaideb, Hussein Raef et al. Jan 10, 2026 pp. 628-628 10.1200/jco.2026.44.2_suppl.628

628 Background: Peptide receptor radionuclide therapy (PRRT) is one of the standard treatments for unresectable or metasta...

Real-world outcomes for pembrolizumab in MSI-high (MSI-H) advanced colorectal cancer (CRC).

Ruba Ahmed Hamed, Edwina Johnston, Walaa Elriah et al. Jan 10, 2026 pp. 223-223 10.1200/jco.2026.44.2_suppl.223

223 Background: 5-year follow-up data from the KEYNOTE-177 trial have demonstrated an overall survival (OS) benefit for pe...

Design of a hybrid site and decentralized clinical research study of an early detection blood test for colorectal cancer.

Sarah Sawyer, Sonali Kotagiri, Uyen Do et al. Jan 10, 2026 10.1200/jco.2026.44.2_suppl.tps245

TPS245 Background: Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related...

Total neoadjuvant treatment in locally advanced rectal cancer: A retrospective multicentre cohort analysis in three cancer centres in Brazil.

Rafael Vanin De Moraes, Elson Santos Neto, Luciano Ipolito Branquinho et al. Jan 10, 2026 pp. 77-77 10.1200/jco.2026.44.2_suppl.77

77 Background: Total neoadjuvant therapy (TNT) improves overall survival (OS) while maintaining local recurrence-free surv...

GATA6 expression with CA19-9 levels as biomarkers in resectable pancreatic adenocarcinoma treated with neoadjuvant modified FOLFIRINOX in the NeoPancONE trial.

Rich Ericson King, Ronan Andrew McLaughlin, Derek J. Jonker et al. Jan 10, 2026 pp. 772-772 10.1200/jco.2026.44.2_suppl.772

772 Background: The increasing use of neoadjuvant systemic therapy for resectable pancreatic adenocarcinoma (rPDAC) highli...

Pathologic determinants of ctDNA-shedding in colorectal cancer metastases.

Hiroki Yukami, Hideaki Bando, Yu Aoki et al. Jan 10, 2026 pp. 183-183 10.1200/jco.2026.44.2_suppl.183

183 Background: In colorectal cancer (CRC), the concordance of genomic alterations between plasma-derived ctDNA and matche...

Antibody-mediated blockade of gremlin-1 in combination with gemcitabine or MEK inhibition in a genetically engineered mouse model of pancreatic cancer.

T.R. Jeffry Evans, Paul Jones, Saadia Karim et al. Jan 10, 2026 pp. 705-705 10.1200/jco.2026.44.2_suppl.705

705 Background: The tumor microenvironment encompasses complex interactions between cancer cells, fibroblasts, and immune...

Clinical significance of serum CA125 kinetics as an early predictor of tumor progression in pancreatic cancer patients.

Iori Motoo, Takayuki Ando, Akira Ueda et al. Jan 10, 2026 pp. 768-768 10.1200/jco.2026.44.2_suppl.768

768 Background: Serum carbohydrate antigen 125 (CA125) is a well-established marker for the diagnosis of ovarian cancer. H...

A randomized phase II trial of medical cannabis to reduce symptom burden in patients with newly diagnosed advanced colorectal cancer (CANCOL).

Kendall Lin, Ella Chrenka, Grace Gilmore et al. Jan 10, 2026 10.1200/jco.2026.44.2_suppl.tps252

TPS252 Background: Patients with advanced colorectal cancer often experience persistent and severe symptom burden. Medical...

Long-term sexual health and post-treatment issues among female survivors of anal cancer.

Ann C. Raldow, Dorothy Wiley, Tristan Grogan et al. Jan 10, 2026 pp. 8-8 10.1200/jco.2026.44.2_suppl.8

8 Background: Data on sexual health outcomes and quality of life in long-term female survivors of anal cancer are limited....

Physical activity and molecular residual disease (MRD) in stage III colon cancer: Findings from CALGB (Alliance)/SWOG 80702.

George Q. Zhang, Chao Ma, Qian Shi et al. Jan 10, 2026 pp. 163-163 10.1200/jco.2026.44.2_suppl.163

163 Background: Being physically inactive is an independent predictor of poor outcomes in patients with stage III colon ca...

A pilot study of mobile application–based exercise and nutrition interventions for gastrointestinal cancer patients with low muscle mass during chemotherapy.

Sun Young Kim, Hyehyun Jeong, Kyung Won Kim et al. Jan 10, 2026 pp. 827-827 10.1200/jco.2026.44.2_suppl.827

827 Background: Sarcopenia is linked to poor prognosis in gastrointestinal (GI) cancer patients receiving chemotherapy. Th...

Inappropriate use of tumor markers for GI cancer screening in asymptomatic patients: A systematic review and proposed follow-up framework.

Silvio Matsas, Allan Roberto Bueso Pineda, Sakditad Saowapa et al. Jan 10, 2026 pp. 804-804 10.1200/jco.2026.44.2_suppl.804

804 Background: Serum tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), and alpha...

Test your biomarkers: Real-world perspectives and patient-reported outcomes on biomarker testing from the gastric cancer patient community.

Martha Raymond, Margaret-Ann Simonetta Jan 10, 2026 pp. 303-303 10.1200/jco.2026.44.2_suppl.303

303 Background: Biomarker advancements are reshaping cancer care in the United States and globally, yet disparities and ba...

Use of a vaginal dilator during chemoradiation for anal cancer to mitigate toxicity.

Anya Huth, Bailey Nelson, Jordan Kharofa Jan 10, 2026 pp. 9-9 10.1200/jco.2026.44.2_suppl.9

9 Background: Women with anal cancer are at risk of developing urinary and sexual treatment-related toxicity due to radiat...

Treatment patterns and clinical outcomes of metastatic gastric cancer: Real-world evidence from retrospective electronic medical records data.

Sun Young Rha, Eunah Kim, Ju-Young Shin et al. Jan 10, 2026 pp. 329-329 10.1200/jco.2026.44.2_suppl.329

329 Background: Five-year survival of patients with metastatic gastric cancer (mGC) is poor. Tumor characteristics, timing...

Toripalimab plus hepatic artery infusion chemotherapy in hepatocellular carcinoma patients of Barcelona Clinic Liver Cancer stage C: A biomolecular exploratory, phase II trial.

Rongce Zhao, Jing Zhou, Zehao Zheng et al. Jan 10, 2026 pp. 536-536 10.1200/jco.2026.44.2_suppl.536

536 Background: Hepatic arterial infusion chemotherapy (HAIC), and immune checkpoint inhibitors showed promising results f...

Survival benefit of nutritional support in advanced gastric cancer patients receiving chemotherapy: A propensity score–matched study.

Keiji Sugiyama, Takumi Ito, Masahiro Yaguchi et al. Jan 10, 2026 pp. 354-354 10.1200/jco.2026.44.2_suppl.354

354 Background: Malnutrition is highly prevalent among patients with advanced gastric cancer (AGC) and is known to impair...

Longitudinal study on the influence of physical activity in managing cancer-related fatigue in patients with colorectal cancer.

Louisa Liu, Elham Kazemian, Nicole Loroña et al. Jan 10, 2026 pp. 16-16 10.1200/jco.2026.44.2_suppl.16

16 Background: Cancer-related fatigue (CRF) is a prevalent and debilitating symptom among patients with colorectal cancer....

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page